{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:17:43Z","timestamp":1791494263962,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T00:00:00Z","timestamp":1406764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T00:00:00Z","timestamp":1406764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1038\/jhh.2014.64","type":"journal-article","created":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T09:18:46Z","timestamp":1406798326000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis"],"prefix":"10.1038","volume":"29","author":[{"given":"G","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X-X","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-L","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R-T","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X-H","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,31]]},"reference":[{"key":"BFjhh201464_CR1","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","volume":"57","author":"SD Persell","year":"2011","unstructured":"Persell SD . Prevalence of resistant hypertension in the United States, 2003\u20132008. Hypertension 2011; 57: 1076\u20131080.","journal-title":"Hypertension"},{"key":"BFjhh201464_CR2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","volume":"57","author":"A De la Sierra","year":"2011","unstructured":"De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 898\u2013902.","journal-title":"Hypertension"},{"key":"BFjhh201464_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/HCO.0b013e328353ad6e","volume":"27","author":"DR Roberie","year":"2012","unstructured":"Roberie DR, Elliott WJ . What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol 2012; 27: 386\u2013391.","journal-title":"Curr Opin Cardiol"},{"key":"BFjhh201464_CR4","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jacc.2008.08.036","volume":"52","author":"PA Sarafidis","year":"2008","unstructured":"Sarafidis PA, Bakris GL . Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52: 1749\u20131757.","journal-title":"J Am Coll Cardiol"},{"key":"BFjhh201464_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11906-011-0226-7","volume":"13","author":"GE Sander","year":"2011","unstructured":"Sander GE, Giles TD . Resistant hypertension: concepts and approach to management. Curr Hypertens Rep 2011; 13: 347\u2013355.","journal-title":"Curr Hypertens Rep"},{"key":"BFjhh201464_CR6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","volume":"51","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for high blood pressure research. Hypertension 2008; 51: 1403\u20131419.","journal-title":"Hypertension"},{"key":"BFjhh201464_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cjca.2012.03.010","volume":"28","author":"D Clark 3rd","year":"2012","unstructured":"Clark D 3rd, Ahmed MI, Calhoun DA . Resistant hypertension and aldosterone: an update. Can J Cardiol 2012; 28: 318\u2013325.","journal-title":"Can J Cardiol"},{"key":"BFjhh201464_CR8","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1097\/HJH.0b013e328363823f","volume":"31","author":"G Brambilla","year":"2013","unstructured":"Brambilla G, Bombelli M, Seravalle G, Cifkova R, Laurent S, Narkiewicz K et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens 2013; 31: 2018\u20132024.","journal-title":"J Hypertens"},{"key":"BFjhh201464_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jama.1966.03110240051022","volume":"198","author":"RL Wolf","year":"1966","unstructured":"Wolf RL, Mendlowitz M, Roboz J, Styan GP, Kornfeld P, Weigl A . Treatment of hypertension with spironolactone. Double-blind study. JAMA 1966; 198: 1143\u20131149.","journal-title":"JAMA"},{"key":"BFjhh201464_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/archinte.1967.00290210057001","volume":"119","author":"LC Johnston","year":"1967","unstructured":"Johnston LC, Grieble HG . Treatment of arterial hypertensive disease with diuretics. V. Spironolactone, an aldosterone antagonist. Arch Intern Med 1967; 119: 225\u2013231.","journal-title":"Arch Intern Med"},{"key":"BFjhh201464_CR11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P . Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892\u2013896.","journal-title":"Hypertension"},{"key":"BFjhh201464_CR12","first-page":"75","volume":"22","author":"R Abolghasmi","year":"2011","unstructured":"Abolghasmi R, Taziki O . Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J Kidney Dis Transpl 2011; 22: 75\u201378.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"BFjhh201464_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","volume":"57","author":"J Vaclavik","year":"2011","unstructured":"Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069\u20131075.","journal-title":"Hypertension"},{"key":"BFjhh201464_CR14","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","volume":"31","author":"CS Oxlund","year":"2013","unstructured":"Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA . Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: A double blind randomized clinical trial. J Hypertens 2013; 31: 2094\u20132102.","journal-title":"J Hypertens"},{"key":"BFjhh201464_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/HJH.0b013e32835b71d6","volume":"31","author":"PM Jansen","year":"2013","unstructured":"Jansen PM, Frenkel WJ, van den Born BJ, de Bruijne EL, Deinum J, Kerstens MN et al. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. J Hypertension 2013; 31: 404\u2013413.","journal-title":"J Hypertension"},{"key":"BFjhh201464_CR16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA . Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925\u2013930.","journal-title":"Am J Hypertens"},{"key":"BFjhh201464_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","volume":"25","author":"DA Lane","year":"2007","unstructured":"Lane DA, Shah S, Beevers DG . Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25: 891\u2013894.","journal-title":"J Hypertens"},{"key":"BFjhh201464_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839\u2013845.","journal-title":"Hypertension"},{"key":"BFjhh201464_CR19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","volume":"2","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, White WB . Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2: 462\u2013468.","journal-title":"J Am Soc Hypertens"},{"key":"BFjhh201464_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jash.2010.10.001","volume":"4","author":"M Engbaek","year":"2010","unstructured":"Engbaek M, Hjerrild M, Hallas J, Jacobsen IA . The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens 2010; 4: 290\u2013294.","journal-title":"J Am Soc Hypertens"},{"key":"BFjhh201464_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","volume":"55","author":"F de Souza","year":"2010","unstructured":"de Souza F, Muxfeldt E, Fiszman R, Salles G . Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55: 147\u2013152.","journal-title":"Hypertension"},{"key":"BFjhh201464_CR22","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1097\/HJH.0b013e32833d4c99","volume":"28","author":"B Alvarez-Alvarez","year":"2010","unstructured":"Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N . Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010; 28: 2329\u20132335.","journal-title":"J Hypertens"},{"key":"BFjhh201464_CR23","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/jhh.2009.96","volume":"24","author":"K Gaddam","year":"2010","unstructured":"Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010; 24: 532\u2013537.","journal-title":"J Hum Hypertens"},{"key":"BFjhh201464_CR24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/jhh.2011.60","volume":"26","author":"R Pisoni","year":"2012","unstructured":"Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens 2012; 26: 502\u2013506.","journal-title":"J Hum Hypertens"},{"key":"BFjhh201464_CR25","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.","journal-title":"PLoS Med"},{"key":"BFjhh201464_CR26","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed on 8 October 2012."},{"key":"BFjhh201464_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG . Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557\u2013560.","journal-title":"BMJ"},{"key":"BFjhh201464_CR28","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/HYPERTENSIONAHA.111.180497","volume":"58","author":"MR Hanselin","year":"2011","unstructured":"Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV . Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension 2011; 58: 1008\u20131013.","journal-title":"Hypertension"},{"key":"BFjhh201464_CR29","first-page":"CD008169","volume":"4","author":"J Batterink","year":"2010","unstructured":"Batterink J, Stabler SN, Tejani AM, Fowkes CT . Spironolactone for hypertension. Cochrane Database Syst Rev 2010; 4: CD008169.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFjhh201464_CR30","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/bcp.12012","volume":"75","author":"LJ Hu","year":"2013","unstructured":"Hu LJ, Chen YQ, Deng SB, Du JL, She Q . Additional use of an aldosterone antagonist in patients with mild to moderate chronic heartfailure: a systematic review and meta-analysis. Br J Clin Pharmacol 2013; 75: 1202\u20131212.","journal-title":"Br J Clin Pharmacol"},{"key":"BFjhh201464_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/CIRCHEARTFAILURE.112.000074","volume":"6","author":"X Li","year":"2013","unstructured":"Li X, Qi Y, Li Y, Zhang S, Guo S, Chu S et al. Function of left ventricular dysfunction: a meta-analysis of randomized controlled impact of mineralocorticoid receptor antagonists on changes in cardiac structure and trials. Circ Heart Fail 2013; 6: 156\u2013165.","journal-title":"Circ Heart Fail"},{"key":"BFjhh201464_CR32","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2215\/CJN.04750908","volume":"4","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF . Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542\u2013551.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFjhh201464_CR33","doi-asserted-by":"publisher","first-page":"40A","DOI":"10.1016\/0002-9149(93)90244-7","volume":"71","author":"DC Schohn","year":"1993","unstructured":"Schohn DC, Jahn HA, Pelletier BC . Dose-related cardiovascular effects of spironolactone. Am J Cardiol 1993; 71: 40A\u201345A.","journal-title":"Am J Cardiol"},{"key":"BFjhh201464_CR34","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.HYP.36.4.594","volume":"36","author":"DM Lloyd-Jones","year":"2000","unstructured":"Lloyd-Jones DM, Evans JC, Larson MG, O\u2019Donnell CJ, Rocella EJ, Levy D . Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36: 594\u2013599.","journal-title":"Hypertension"},{"key":"BFjhh201464_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/01.mnh.0000214775.42103.a5","volume":"15","author":"Z Pausova","year":"2006","unstructured":"Pausova Z . From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens 2006; 15: 173\u2013178.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFjhh201464_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"WC Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393\u2013404.","journal-title":"J Clin Hypertens"},{"key":"BFjhh201464_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med 1999; 341: 709\u2013717.","journal-title":"New Engl J Med"},{"key":"BFjhh201464_CR38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000237742","volume":"30","author":"N Khosla","year":"2009","unstructured":"Khosla N, Kalaitzidis R, Bakris GL . Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30: 418\u2013424.","journal-title":"Am J Nephrol"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh201464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201464","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T18:47:52Z","timestamp":1647542872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh201464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,31]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["BFjhh201464"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2014.64","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,31]]},"assertion":[{"value":"17 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}